Is TG Therapeutics Inc. (TGTX) A Good Investment?


TG Therapeutics Inc. (NASDAQ:TGTX) finished Thursday with an addition of $1.94 to close at $10.40, an upside of 22.93 percent. An average of 15,347,920 shares of common stock have been traded in the last five days. There was a gain of $1.57 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 6,711,545 shares traded, while the 50-day average volume stands at 4,372,026.

TGTX stock has increased by 27.92% in the last month. The company shares reached their 1-month lowest point of $6.88 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $3.48 and a high of $20.69 in 52 weeks. It has reached a new high 1 time so far this year and lost -45.26% or -$8.60 in price. In spite of this, the price is down -49.73% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

TGTX stock investors should be aware that TG Therapeutics Inc. (TGTX) stock had its last reported insider trading activity 359 days ago on Jan 05. In this transaction, the insider spent $561,586. CFO, Secretary and Treasurer, Power Sean A, disposed of 9,653 shares at a price of $18.31 on Jan 05. The insider now owns more than $176,746 worth of shares. Prior to that, CFO, Secretary and Treasurer Power Sean A went on to Sale 75,312 shares at $19.20 each on Jan 04. An amount of $1,445,990 was transacted.

Valuation Metrics

TG Therapeutics Inc. (TGTX) stock’s beta is 2.18. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 319.43, the price-to-book (PB) ratio at 14.05.

Financial Health

The quick ratio of TG Therapeutics Inc. for the three months ended September 29 was 5.00, and the current ratio was 5.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.70 and a total debt to equity ratio of 0.70 for the quarter ending September 29. Its gross profit as reported stood at $5.9 million compared to revenue of $6.69 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, TG Therapeutics Inc.’s return on assets was -82.90%.

Earnings Surprise

For the three-month period that ended September 29, TG Therapeutics Inc. had $66.08 million in cash and short-term investments compared to $70.04 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$35.82 million in the quarter, while revenues were shrunk -139.08%. The analyst consensus anticipated TG Therapeutics Inc.’s latest quarter earnings to come in at -$0.34 per share, but it turned out to be -$0.26, a 23.50% surprise. For the quarter, EBITDA amounted to -$34.53 million. Shareholders own equity worth $145.34 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at TG Therapeutics Inc. (TGTX) price momentum. RSI 9-day as of the close on 29 December was 69.68%, suggesting the stock is Neutral, with historical volatility in this time frame at 131.32%.

As of today, TGTX’s price is $8.68 +17.78% or $1.57 from its 5-day moving average. TGTX is currently trading +17.91% higher than its 20-day SMA and +38.30% higher than its 100-day SMA. However, the stock’s current price level is +82.14% above the SMA50 and +30.16% above the SMA200.

The stochastic %K and %D were 43.40% and 33.75%, respectively, and the average true range (ATR) was 1.36. With the 14-day stochastic at 76.52% and the average true range at 1.14, the RSI (14) stands at 65.32%. The stock has reached 0.37 on the 9-day MACD Oscillator while the 14-day reading was at 0.35.

Analyst Ratings

BofA Securities launched coverage on TG Therapeutics Inc. (NASDAQ: TGTX) in its analyst report released on May 20, 2022. The firm assigned the stock an Underperform rating. The consensus rating for TG Therapeutics Inc. (TGTX) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell TGTX, while 0 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.

What is TGTX’s price target for the next 12 months?

Analysts predict a range of price targets between $6.00 and $40.00, with a median target of $21.00. Taking a look at these predictions, the average price target given by analysts for TG Therapeutics Inc. (TGTX) stock is $19.56.


Please enter your comment!
Please enter your name here